Cumberland Pharmaceuticals (NASDAQ:CPIX) Stock Price Passes Above 200-Day Moving Average - Here's What Happened

Key Points

• Cumberland Pharmaceuticals shares moved above their 200-day moving average, reaching $6.74 before closing at $6.64, compared with the $5.48 long-term average.
• Despite the technical gain, analyst sentiment remains negative: Weiss Ratings reaffirmed a “sell (D-)” rating, and MarketBeat reported a consensus “Sell” rating.
• The company reported a quarterly loss of $0.20 per share, missing the $0.13-per-share estimate, while revenue of $0.17 million fell far short of the $8.50 million consensus forecast.

Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX - Get Free Report) shares crossed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $5.48 and traded as high as $6.74. Cumberland Pharmaceuticals shares last traded at $6.64, with a volume of 26,890 shares traded.

Analysts Set New Price Targets

Separately, Weiss Ratings reissued a "sell (d-)" rating on shares of Cumberland Pharmaceuticals in a research note on Wednesday, June 24th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Cumberland Pharmaceuticals currently has a consensus rating of "Sell".

Cumberland Pharmaceuticals Stock Performance

The stock's 50 day simple moving average is $7.22 and its two-hundred day simple moving average is $5.48. The firm has a market capitalization of $99.47 million, a PE ratio of -9.35 and a beta of 0.13.

Cumberland Pharmaceuticals (NASDAQ:CPIX - Get Free Report) last announced its quarterly earnings data on Tuesday, August 4th. The specialty pharmaceutical company reported ($0.20) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.13) by ($0.07). Cumberland Pharmaceuticals had a negative net margin of 34.40% and a negative return on equity of 28.81%. The firm had revenue of $0.17 million during the quarter, compared to analysts' expectations of $8.50 million.

Cumberland Pharmaceuticals Dividend Announcement

The company also recently declared a dividend, which was paid on Friday, July 31st. Stockholders of record on Thursday, July 23rd were paid a $1.50 dividend.

Institutional Trading of Cumberland Pharmaceuticals

Several institutional investors have recently made changes to their positions in CPIX. Dimensional Fund Advisors LP lifted its holdings in Cumberland Pharmaceuticals by 1.5% in the first quarter. Dimensional Fund Advisors LP now owns 276,359 shares of the specialty pharmaceutical company's stock valued at $898,000 after acquiring an additional 4,081 shares during the last quarter. BlackRock Inc. acquired a new stake in Cumberland Pharmaceuticals during the second quarter worth $412,000. Bank of New York Mellon Corp acquired a new stake in Cumberland Pharmaceuticals during the second quarter worth $379,000. Finally, Arrowstreet Capital Limited Partnership purchased a new stake in Cumberland Pharmaceuticals in the first quarter valued at $66,000. Hedge funds and other institutional investors own 15.51% of the company's stock.

About Cumberland Pharmaceuticals

Cumberland Pharmaceuticals Inc NASDAQ: CPIX is a specialty pharmaceutical company based in Nashville, Tennessee, focused on the development, manufacture and commercialization of hospital and acute care products. Founded in 1993, the company has built a portfolio of branded therapeutics designed to address critical care needs in emergency medicine, critical care units and other hospital settings. Cumberland's strategy emphasizes in-licensing and acquiring products that have established safety and efficacy profiles but limited market reach, then leveraging its sales network to expand their commercial footprint.

The company's flagship products include Acetadote (N-acetylcysteine injection), the only FDA-approved antidote for acetaminophen overdose administered intravenously; Vasostrict (vasopressin injection), used to raise blood pressure in adults with vasodilatory shock; Cerebrex (diclofenac sodium injection), an anti-inflammatory agent for managing acute pain and fever; and Dynastat (parecoxib sodium), a COX-2 inhibitor for postoperative pain relief.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.